BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11358825)

  • 1. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
    van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
    Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.
    van Spriel AB; van den Herik-Oudijk IE; van Sorge NM; Vilé HA; van Strijp JA; van de Winkel JG
    J Infect Dis; 1999 Mar; 179(3):661-9. PubMed ID: 9952373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
    Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
    J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI.
    Otten MA; Leusen JH; Rudolph E; van der Linden JA; Beelen RH; van de Winkel JG; van Egmond M
    J Immunol; 2007 Sep; 179(5):2918-24. PubMed ID: 17709506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction.
    Bakema JE; de Haij S; den Hartog-Jager CF; Bakker J; Vidarsson G; van Egmond M; van de Winkel JG; Leusen JH
    J Immunol; 2006 Mar; 176(6):3603-10. PubMed ID: 16517729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression and function of IgA receptors (CD89 and CD71) during maturation of dendritic cells.
    Pasquier B; Lepelletier Y; Baude C; Hermine O; Monteiro RC
    J Leukoc Biol; 2004 Dec; 76(6):1134-41. PubMed ID: 15371488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.
    Otten MA; Rudolph E; Dechant M; Tuk CW; Reijmers RM; Beelen RH; van de Winkel JG; van Egmond M
    J Immunol; 2005 May; 174(9):5472-80. PubMed ID: 15843545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain.
    Bakema JE; Hiemstra IH; Bakker J; de Haij S; Kok Y; Adema G; van Egmond M; Coffer PJ; van de Winkel JG; Leusen JH
    Eur J Immunol; 2010 Jul; 40(7):2035-40. PubMed ID: 20411563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.
    Bakema JE; Ganzevles SH; Fluitsma DM; Schilham MW; Beelen RH; Valerius T; Lohse S; Glennie MJ; Medema JP; van Egmond M
    J Immunol; 2011 Jul; 187(2):726-32. PubMed ID: 21653835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.
    Stockmeyer B; Elsässer D; Dechant M; Repp R; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol Methods; 2001 Feb; 248(1-2):103-11. PubMed ID: 11223072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcalphaRI (CD89) improves in vitro clearance by gingival crevicular neutrophils.
    Kobayashi T; Takauchi A; van Spriel AB; Vilé HA; Hayakawa M; Shibata Y; Abiko Y; van de Winkel JG; Yoshie H
    Vaccine; 2004 Dec; 23(5):585-94. PubMed ID: 15542178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosslinking of the human Fc receptor for IgA (FcalphaRI/CD89) triggers FcR gamma-chain-dependent shedding of soluble CD89.
    van Zandbergen G; Westerhuis R; Mohamad NK; van De Winkel JG; Daha MR; van Kooten C
    J Immunol; 1999 Dec; 163(11):5806-12. PubMed ID: 10570263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.